Key result
Bioresorbable vascular scaffolds represent a promising technology for STEMI, but current evidence is limited to small studies with short-term follow-up, necessitating larger trials to confirm safety and efficacy.
Why the study?
Does bioresorbable vascular scaffold implantation improve clinical outcomes and vascular healing compared to metallic stents in patients with ST-segment elevation myocardial infarction?
Does bioresorbable vascular scaffold implantation improve clinical outcomes and vascular healing compared to metallic stents in patients with ST-segment elevation myocardial infarction?
While BVS offers theoretical advantages for vascular restoration in STEMI, current evidence is limited to small studies showing high procedural success but raising concerns about early scaffold thrombosis, necessitating optimized implantation techniques and larger long-term trials.
BVS use in STEMI warrants caution outside trials; leaves open long-term safety versus drug-eluting stents.
Bioresorbable vascular scaffolds (BVS) represent a breakthrough technology for percutaneous coronary intervention (PCI). In this context, because of the unique properties of bioresorbable devices, ST-segment elevation myocardial infarction (STEMI) may represent the ideal scenario for BVS implantation. Consistently, 57% of physicians declare they currently use BVS in this group of patients. However, continuous and growing evidence on the good performance of these devices has been actually shown only in small studies with short- and mid-term follow-up. For these reasons, we need data from sufficiently large observational studies, with long-term follow-up, to confirm that BVS can deliver the same results as 2nd-generation drug-eluting stents when using an appropriate implantation technique. In this review, we discuss the potential advantages of BVS implantation in STEMI patients, together with the most recent evidence from clinical studies, highlighting safety and procedural concerns.
No takes yet. Share an insight, caveat, or question.
Scalone et al. (2015) conducted a review in ST-segment elevation myocardial infarction (STEMI). Bioresorbable vascular scaffolds (BVS) vs. Drug-eluting stents (DES) was evaluated. Bioresorbable vascular scaffolds represent a promising technology for STEMI, but current evidence is limited to small studies with short-term follow-up, necessitating larger trials to confirm safety and efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: